ReBio Information

View Top Employees from ReBio

ReBio Pharma is a European biotechnology company developing novel, targeted, vision-preserving therapies for ocular oncology that achieve precise exposure at the site of disease. The lead program, RBP-01, applies a proprietary therapeutic amplifier technology to deliver potent, localized tumor control in uveal melanoma. ReBio is advancing RBP-01 toward the clinic (Q1 2026), while pursuing the development of additional assets targeting uveal melanoma and retinoblastoma, expanding therapeutic possibilities of existing treatments with targeted drug exposure. For more information, please visit www.rebiopharma.com

Website	http://www.rebiopharma.com
Employees	25 (7 on RocketReach)
Founded	2015
Industry	Biotechnology
Keywords	Drug Formulation, Pharmaceutical Technology, Novel Drug Delivery Systems, Controlled Release Formulations, Innovative Drug Delivery, Biotechnology, Preclinical Development, Therapeutic Drug Delivery, Advanced Drug Delivery, Drug Delivery Research, Proprietary Technology, Pharmaceutical Development, Pharmaceutical Research, Targeted Drug Delivery, Nanoparticle Drug Delivery
Competitors	Amgen, Gilead Sciences, Genentech, Regeneron, Biogen, Receptos, a wholly-owned subsidiary of Celgene, Sangamo Therapeutics, Inc., Vertex Pharmaceuticals, Lilly India, AstraZeneca +44 more (view full list)